October 2025: semaglutide (Rybelsus) Novo Nordisk submitted a supplemental new drug application (sNDA) to the FDA for oral semaglutide (Rybelsus) to reduce the risk of major adverse cardiovascular events (cardiovascular [CV] death, non-fatal heart attack or non-fatal stroke) in people with type 2 diabetes (T2DM) and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD)
Cherchi A, Lai C, Angelino F, et al
Front Plant Sci 7:531 Sharon-Gojman R, Maimon E, Leu S, Zarka A, Boussiba S (2015) Advanced methods for genetic engineering of Haematococcus pluvialis ( Chlorophyceae , Volvocales )
Okay, so why dont we just consume these foods and forget about therapy
NAION, also called an eye stroke, occurs when there is less blood flow to the optic nerve, leading to sudden, painless vision loss
All studies found an effect of ES on at least one of the behavioral domains and will be discussed below